Advicenne shares were listed on Euronext Paris on December 6, 2017.
ISIN code: FR0013296746
Number of outstanding shares: 8 062 344
Eligible for PEA and PEA-PME
Click here for live stock price.
|Gilbert Dupont : Guillaume Cuvillier, Jamila El Bougrini|
|NIBC : Dylan van Haaften, Anita Ye|
Ownership Structure on January 5, 2018
Analyst Coverage of ADVIC (Contact Details)
Dr. Samir Devani
Jamila El Bougrini, Ph.D., M.B.A.
Dylan van Haaften & Anita Ye
Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Paris and Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France.
© 2019 Advicenne